These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 39273015)

  • 21. Dissecting the Role of BET Bromodomain Proteins BRD2 and BRD4 in Human NK Cell Function.
    Cribbs AP; Filippakopoulos P; Philpott M; Wells G; Penn H; Oerum H; Valge-Archer V; Feldmann M; Oppermann U
    Front Immunol; 2021; 12():626255. PubMed ID: 33717143
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epigenetic reader BRD4 inhibition as a therapeutic strategy to suppress E2F2-cell cycle regulation circuit in liver cancer.
    Hong SH; Eun JW; Choi SK; Shen Q; Choi WS; Han JW; Nam SW; You JS
    Oncotarget; 2016 May; 7(22):32628-40. PubMed ID: 27081696
    [TBL] [Abstract][Full Text] [Related]  

  • 23. BET bromodomain inhibition of MYC-amplified medulloblastoma.
    Bandopadhayay P; Bergthold G; Nguyen B; Schubert S; Gholamin S; Tang Y; Bolin S; Schumacher SE; Zeid R; Masoud S; Yu F; Vue N; Gibson WJ; Paolella BR; Mitra SS; Cheshier SH; Qi J; Liu KW; Wechsler-Reya R; Weiss WA; Swartling FJ; Kieran MW; Bradner JE; Beroukhim R; Cho YJ
    Clin Cancer Res; 2014 Feb; 20(4):912-25. PubMed ID: 24297863
    [TBL] [Abstract][Full Text] [Related]  

  • 24. BRD3 and BRD4 BET Bromodomain Proteins Differentially Regulate Skeletal Myogenesis.
    Roberts TC; Etxaniz U; Dall'Agnese A; Wu SY; Chiang CM; Brennan PE; Wood MJA; Puri PL
    Sci Rep; 2017 Jul; 7(1):6153. PubMed ID: 28733670
    [TBL] [Abstract][Full Text] [Related]  

  • 25. BRD4 associates with p53 in DNMT3A-mutated leukemia cells and is implicated in apoptosis by the bromodomain inhibitor JQ1.
    Stewart HJ; Horne GA; Bastow S; Chevassut TJ
    Cancer Med; 2013 Dec; 2(6):826-35. PubMed ID: 24403256
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting BRD4 proteins suppresses the growth of NSCLC through downregulation of eIF4E expression.
    Gao Z; Yuan T; Zhou X; Ni P; Sun G; Li P; Cheng Z; Wang X
    Cancer Biol Ther; 2018 May; 19(5):407-415. PubMed ID: 29333921
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting STAT5 in hematologic malignancies through inhibition of the bromodomain and extra-terminal (BET) bromodomain protein BRD2.
    Liu S; Walker SR; Nelson EA; Cerulli R; Xiang M; Toniolo PA; Qi J; Stone RM; Wadleigh M; Bradner JE; Frank DA
    Mol Cancer Ther; 2014 May; 13(5):1194-205. PubMed ID: 24435449
    [TBL] [Abstract][Full Text] [Related]  

  • 28. BET Bromodomain Inhibition Potentiates Ocular Melanoma Therapy by Inducing Cell Cycle Arrest.
    Chen X; Huang R; Zhang Z; Song X; Shen J; Wu Q
    Invest Ophthalmol Vis Sci; 2024 Jul; 65(8):11. PubMed ID: 38967943
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bromodomains and Extra-Terminal (BET) Inhibitor JQ1 Suppresses Proliferation of Acute Lymphocytic Leukemia by Inhibiting c-Myc-Mediated Glycolysis.
    Zhang MY; Liu SL; Huang WL; Tang DB; Zheng WW; Zhou N; Zhou H; Abudureheman T; Tang ZH; Zhou BS; Duan CW
    Med Sci Monit; 2020 Apr; 26():e923411. PubMed ID: 32266878
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting Hippo coactivator YAP1 through BET bromodomain inhibition in esophageal adenocarcinoma.
    Song S; Li Y; Xu Y; Ma L; Pool Pizzi M; Jin J; Scott AW; Huo L; Wang Y; Lee JH; Bhutani MS; Weston B; Shanbhag ND; Johnson RL; Ajani JA
    Mol Oncol; 2020 Jun; 14(6):1410-1426. PubMed ID: 32175692
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dual targeting of mTOR and aurora-A kinase for the treatment of uterine Leiomyosarcoma.
    Brewer Savannah KJ; Demicco EG; Lusby K; Ghadimi MP; Belousov R; Young E; Zhang Y; Huang KL; Lazar AJ; Hunt KK; Pollock RE; Creighton CJ; Anderson ML; Lev D
    Clin Cancer Res; 2012 Sep; 18(17):4633-45. PubMed ID: 22821997
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interactome Rewiring Following Pharmacological Targeting of BET Bromodomains.
    Lambert JP; Picaud S; Fujisawa T; Hou H; Savitsky P; Uusküla-Reimand L; Gupta GD; Abdouni H; Lin ZY; Tucholska M; Knight JDR; Gonzalez-Badillo B; St-Denis N; Newman JA; Stucki M; Pelletier L; Bandeira N; Wilson MD; Filippakopoulos P; Gingras AC
    Mol Cell; 2019 Feb; 73(3):621-638.e17. PubMed ID: 30554943
    [TBL] [Abstract][Full Text] [Related]  

  • 33. BET bromodomain inhibitors--a novel epigenetic approach in castration-resistant prostate cancer.
    Lochrin SE; Price DK; Figg WD
    Cancer Biol Ther; 2014; 15(12):1583-5. PubMed ID: 25535892
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synergistic efficacy of inhibiting MYCN and mTOR signaling against neuroblastoma.
    Kling MJ; Griggs CN; McIntyre EM; Alexander G; Ray S; Challagundla KB; Joshi SS; Coulter DW; Chaturvedi NK
    BMC Cancer; 2021 Sep; 21(1):1061. PubMed ID: 34565342
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sleeping Beauty Transposon Mutagenesis Identifies Genes Driving the Initiation and Metastasis of Uterine Leiomyosarcoma.
    Kodama M; Shimura H; Tien JC; Newberg JY; Kodama T; Wei Z; Rangel R; Yoshihara K; Kuruma A; Nakae A; Hashimoto K; Sawada K; Kimura T; Jenkins NA; Copeland NG
    Cancer Res; 2021 Nov; 81(21):5413-5424. PubMed ID: 34475109
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sensitivity of Small Cell Lung Cancer to BET Inhibition Is Mediated by Regulation of ASCL1 Gene Expression.
    Lenhart R; Kirov S; Desilva H; Cao J; Lei M; Johnston K; Peterson R; Schweizer L; Purandare A; Ross-Macdonald P; Fairchild C; Wong T; Wee S
    Mol Cancer Ther; 2015 Oct; 14(10):2167-74. PubMed ID: 26253517
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biological and molecular effects of bromodomain and extra-terminal (BET) inhibitors JQ1, IBET-151, and IBET-762 in OSCC cells.
    Baldan F; Allegri L; Lazarevic M; Catia M; Milosevic M; Damante G; Milasin J
    J Oral Pathol Med; 2019 Mar; 48(3):214-221. PubMed ID: 30618144
    [TBL] [Abstract][Full Text] [Related]  

  • 38. BET bromodomain protein inhibition is a therapeutic option for medulloblastoma.
    Henssen A; Thor T; Odersky A; Heukamp L; El-Hindy N; Beckers A; Speleman F; Althoff K; Schäfers S; Schramm A; Sure U; Fleischhack G; Eggert A; Schulte JH
    Oncotarget; 2013 Nov; 4(11):2080-95. PubMed ID: 24231268
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bromodomain and extra-terminal domain (BET) proteins regulate melanocyte differentiation.
    Trivedi A; Mehrotra A; Baum CE; Lewis B; Basuroy T; Blomquist T; Trumbly R; Filipp FV; Setaluri V; de la Serna IL
    Epigenetics Chromatin; 2020 Mar; 13(1):14. PubMed ID: 32151278
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BET-Inhibitors Disrupt Rad21-Dependent Conformational Control of KSHV Latency.
    Chen HS; De Leo A; Wang Z; Kerekovic A; Hills R; Lieberman PM
    PLoS Pathog; 2017 Jan; 13(1):e1006100. PubMed ID: 28107481
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.